Physician profile
Songhui Ma
NPI 1508857046
$5,884.06
in general payments reported to CMS, 2019-2025
23 companies · $723 in 2025
The $723 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $151 · 2021: $2,013 · 2022: $2,548 · 2024: $34.86 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,493.90 | 2019-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,008.54 | 2020-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $731.97 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $554.06 | 2020-2022 | |
| Kaleo, INC. | $265.48 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $260.23 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $250.07 | 2021-2022 | |
| Optinose US, INC. | $237.03 | 2019-2022 | |
| Alk-Abello, INC | $185.42 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $168.05 | 2021-2022 | |
| Amgen INC. | $161.91 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.27 | 2020-2022 | |
| Pharming Healthcare, INC. | $107.86 | 2021-2025 | Ruconest |
| Genentech USA, INC. | $65.39 | 2019-2021 | |
| Csl Behring | $54.63 | 2025 | Andembry |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $38.34 | 2025 | Dawnzera |
| Takeda Pharmaceuticals U.S.A., INC. | $36.12 | 2021 | |
| Covis Pharma Gmbh | $33.34 | 2021 | |
| Pfizer INC. | $29.54 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $23.39 | 2019 | |
| Incyte Corporation | $19.81 | 2022 | |
| Octapharma USA, INC. | $17.08 | 2025 | Cutaquig |
| Horizon Therapeutics Plc | $15.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Songhui Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.